医学
1型糖尿病
糖尿病酮症酸中毒
低血糖
减肥
糖尿病
内科学
胰岛素
2型糖尿病
超重
随机对照试验
恩帕吉菲
辅助治疗
观察研究
不利影响
2型糖尿病
叙述性评论
临床试验
格列美脲
重症监护医学
内分泌学
酮症酸中毒
荟萃分析
外科
作者
Konstantinos Kitsios,Christina Trakatelli
标识
DOI:10.1177/15209156261486127
摘要
Automated Insulin Delivery (AID) systems represent the most effective and safe treatment for the management of type 1 diabetes (T1D). Antidiabetic agents used for the treatment of type 2 diabetes, such as the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (RAs), the dual Glucose-dependent Insulinotropic Polypeptide and GLP-1 RA and the Sodium-Glucose co-Transporter 2 inhibitors are associated with clinically significant weight loss and cardioprotective effect. Given the increased prevalence of overweight, obesity, and cardiovascular risk in patients with T1D, the addition of these medications to AID treatment is of considerable clinical interest. In this review limited data from randomized controlled and observational trials show that in overweight and obese patients with T1D treated with AID, the addition of weekly semaglutide, or tirzepatide is associated with significant weight loss, reduction in total daily insulin dose and increase in Time In target Range (TIR) without increased risk for hypoglycemia and Diabetic Ketoacidosis (DKA). Similarly, adjunctive treatment with empagliflozin resulted in increased TIR without increase in hypoglycemia, reduction in insulin requirements, and increase in the mean plasma ketone value, although DKA remained rare. However, studies of longer duration with more participants are required to establish the long-term safety and efficacy of these interventions in patients with T1D treated with AID.
科研通智能强力驱动
Strongly Powered by AbleSci AI